Phase 2a Study of Nasal Foralumab Treatment in Adults 30 to 85 Years With Multiple System Atrophy MSA
Evaluating Safety, Brain Immune Activity, and Clinical Effects
Led by Tiziana Life Sciences LTD · Updated on 2026-06-10
5
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This trial investigates the use of Foralumab Nasal in adults aged 30 to 85 years diagnosed with Multiple System Atrophy MSA, a progressive neurological disorder. It is a Phase 2a study focusing on evaluating microglial activation, safety, and clinical effects of the treatment in this patient population. The study includes patients with clinically established or probable MSA under stable dopaminergic treatment.
Participants will first enter a 6-month observational lead-in phase without active treatment, followed by a 6-month open-label treatment phase. During treatment, Foralumab, an anti-CD3 monoclonal antibody delivered as a nasal spray, will be given in eight 3-week cycles. Each cycle involves intranasal doses three times per week for two weeks, then a one-week break.
Throughout the study, participants will undergo assessments including motor function exams, quality of life questionnaires, brain imaging to measure inflammation and volume changes, and blood tests to monitor safety. Researchers will measure changes in MDS-UMSARS scores and TSPO activity using PET scans over six months. The total participation time is approximately one year including both observation and treatment periods.
CONDITIONS
Brief Title
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
Research Team
B
Brigham and Women's Hospital Movement Research Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Foralumab Nasal
Guideline Symptomatic Care
What it is
A nasal spray formulation of Foralumab, an anti-CD3 monoclonal antibody, is administered as part of an experimental regimen in adults with advanced MSA.
Current symptomatic care for MSA focuses on individualised management of parkinsonian, autonomic, and cerebellar features, often including dopaminergic agents, blood pressure support, and multidisciplinary therapies.
Primary use
Investigational immunomodulation targeting neuroinflammation in MSA, aiming to assess effects on disease activity and clinical symptoms.
Symptomatic management aims to reduce motor symptoms, improve autonomic stability, enhance quality of life, and support daily function.
How it is given or performed
Foralumab is delivered as a nasal spray three times per week for two weeks in each cycle, repeated over eight cycles.
Symptomatic therapy is individualised, typically involving oral dopaminergic drugs, physical therapy, and pharmacological support for autonomic dysfunction (for example, blood pressure medications).
Evidence status
No published results currently available; trial is ongoing, and outcome evidence is not yet established.
Longstanding published evidence supports effectiveness of symptomatic treatments for parkinsonian and autonomic symptoms, though no therapy has been shown to modify disease progression.
Important limitations
This is a single-group early phase study without comparative control; efficacy and safety in the broader population remain to be established.
Symptomatic treatments are limited in their impact and do not halt underlying neurodegeneration; most patients eventually experience progressive disability.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 30Years - 85Years
All Genders
Eligibility Criteria
You may qualify if you...
Clinical diagnosis of Clinically Established or Clinically Probable Multiple System Atrophy per 2022 MDS criteria
Age between 30 and 85 years at informed consent
Stable dopaminergic treatment for at least 4 weeks before enrollment
Hemoglobin ≥ 9 g/dL and platelets ≥ 100 x 10^9 cells/L without transfusion support
Creatinine ≤ 1.5 times upper limit of normal or creatinine clearance ≥ 60 mL/min/1.73 m2
Total bilirubin ≤ 2 times upper limit of normal unless due to Gilbert's disease
ALT and AST ≤ 2.5 times upper limit of normal
QTcF ≤ 470 msec for women and ≤ 450 msec for men on screening ECG
Negative urine pregnancy test within 7 days before first dose for women of child-bearing potential
Use of effective contraception during study and 90 days after treatment for sexually active women and men
Up-to-date immunizations as assessed by primary care physician and neurologist
Ability to provide written informed consent
You will not qualify if you...
Diagnosis or suspicion of other causes of Parkinsonism or alternate neurological diagnosis
Female patients who are pregnant, lactating, breastfeeding, or planning pregnancy during the study
Claustrophobia preventing study procedures
Non-MRI-compatible implanted devices
Low-affinity binders for TSPO PET ligands
Systemic corticosteroid treatment within past 4 weeks (excluding nasal/local treatments)
Brain MRI abnormalities interfering with PET-MRI co-registration
Serious cardiac conditions within last 6 months including uncontrolled arrhythmia, myocardial infarction, unstable angina, NYHA Class III/IV heart disease, or hereditary long QT syndrome
Medications causing QTc prolongation or Torsades de Pointes unless essential for care
Positive tests for HIV, hepatitis B or C, or positive Epstein-Barr virus IgM at screening
Past history of hematologic or solid malignancy
Chronic immunosuppressive treatment within past 90 days
Inability to tolerate nasal medications
Recent use or anticipated need for nasal corticosteroids, antihistamines, or flu dosing
Chronic rhinitis, deviated septum, nasal polyps, or recent sinusitis
Autoimmune or inflammatory conditions such as IBD, rheumatoid arthritis, lupus, Sjögren's syndrome, asthma, or type 1 diabetes
Severe immunosuppression indicated by low neutrophil or lymphocyte counts
History of gadolinium allergy
Recent significant active infection requiring treatment within 15 days
Any medical or surgical condition compromising study adherence or result interpretation
Inability or unwillingness to comply with protocol
Active COVID-19 infection
COVID-19 vaccine within past 10 days or any other vaccine within past 7 days at dosing
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Observational Lead-In Phase
Duration - 6 months
Participants are observed without active treatment for 6 months to establish baseline measures.
Open-Label Treatment Phase
Duration - 6 months
Participants receive Foralumab Nasal in eight 3-week cycles over 6 months. Dosing occurs three times per week for two weeks followed by one week off in each cycle.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Using 18FF-DOPA PET Imaging to Study Dopamine Changes in Adults with Autonomic Failure and Related Disorders
Phase 2a Study of Nasal Foralumab Treatment in Adults 30 to 85 Years With Multiple System Atrophy MSA
Evaluating Safety, Brain Immune Activity, and Clinical Effects
Open-Label Extension Trial to Evaluate the Safety and Tolerability of Oral TEV-56286 in Adults with Multiple System Atrophy
Phase I Study of Autologous Sural Nerve Tissue Grafting to the Brains Substantia Nigra in Parkinsons Disease and Multiple System Atrophy
Study of Alzheimer Biomarkers in Cerebrospinal Fluid for People with Cognitive Disorders
Including Various Neurodegenerative Dementias
Study of Swallowing Rehabilitation Treatment for Adults with Multiple System Atrophy
Studying Continuous Positive Airway Pressure CPAP to Lower Nighttime High Blood Pressure in Adults with Autonomic Failure and Neurogenic Orthostatic Hypotension
Evaluation of Butylphthalide Capsules for Treating Symptoms of Multiple System Atrophy
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Open-Label Study Evaluating ALT001 Nerve Repair Protein Treatment for Multiple System Atrophy Patients in a Real-World Setting
Using Advanced Brain Imaging to Identify Biomarkers for Parkinsons Disease Progression and Diagnosis of Parkinsonian Syndromes
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [11 C]PBR28 and Machine Learning Analysis.
Aurelija Jucaite, Zsolt Cselényi, William C Kreisl...